Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Risk & Volatility
Viridian Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Valuation and Earnings
This table compares Viridian Therapeutics and Invivyd”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Viridian Therapeutics | $70.85 million | 39.66 | -$342.60 million | ($3.37) | -7.36 |
| Invivyd | $53.43 million | 3.32 | -$52.49 million | ($0.33) | -1.82 |
Invivyd has lower revenue, but higher earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
70.4% of Invivyd shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 12.2% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Viridian Therapeutics and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Viridian Therapeutics | -505.86% | -72.97% | -42.80% |
| Invivyd | -183.90% | -59.73% | -48.97% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Viridian Therapeutics and Invivyd, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Viridian Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
| Invivyd | 1 | 2 | 3 | 0 | 2.33 |
Viridian Therapeutics currently has a consensus price target of $38.92, suggesting a potential upside of 56.92%. Invivyd has a consensus price target of $10.00, suggesting a potential upside of 1,561.13%. Given Invivyd’s higher probable upside, analysts clearly believe Invivyd is more favorable than Viridian Therapeutics.
Summary
Invivyd beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
